NGEC Applications Meeting 05-06-08 Mike Certo Scharenberg Lab.

Slides:



Advertisements
Similar presentations
DNA methods summary 1.Restriction enzymes cut at specific DNA sites. (N) 2.Vectors allow genes to be “cloned” and proteins “expressed”. (N) 3.Gel electrophoresis.
Advertisements

RETROVIRUSES.
Homology-directed gene repair Sequence correction xx exogenous repair substrate Rad51… sister chromatids I-SceI.
The analysis of homologous recombination frequency 1.There are two assays (artificial substrates) for double-strand break (DSB) induced homologous recombination.
Targeted gene alteration in Caenorhabditis elegans by gene conversion Peter L Barrett, John T Fleming & Verena Göbel Nat Genet Oct 24.
Gene repair in murine hematopoietic stem cells (NGEC Component 6) Aim 1: Develop and test a murine X-linked severe combined immunodeficiency (XSCID) model.
Lentiviral Design for Delivery of Homing Endonucleases mCherry HA-NLS-HE RSVR U5 hPGK R U5sinU3 Repair Template Cppt RRE RRL Lentiviral Backbone.
MOLECULAR BIOLOGY – Basic Genetics
Monnat Lab progress monomerizations of Cre, Mso (Hui) 2 nd round designs vs. Anopheles targets (Umut) in vivo recombination reporter assays (Ray, Hui)
I-SceI-mediated Genome Editing in the Canine Model Kiem lab Applications Meeting Feb 23, 2009.
Site-Directed Mutagenesis
Nina M. Muñoz Kiem lab May 18th, 2009
Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1
Volume 15, Issue 6, Pages (June 2007)
Volume 16, Issue 3, Pages (March 2008)
Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID.
A B C Gentile et al., Figure 1A Gentile et al., Supplementary Figure 1
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
In vivo optimization of the tagging approach using the Act5C model locus and flow cytometry-based quantification of the Act5C-GFP tagging success. In vivo.
Stimulation of V(D)J recombination by histone acetylation
Molecular Therapy - Methods & Clinical Development
Volume 17, Issue 8, Pages (August 2009)
Volume 15, Issue 1, Pages (January 2007)
Volume 12, Issue 6, Pages (December 2005)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Volume 2, Issue 4, Pages (October 1998)
Volume 10, Issue 1, Pages (July 2004)
Disruption of the BGLF2 gene decreased infectious progeny production.
Volume 154, Issue 6, Pages (September 2013)
Molecular Therapy - Nucleic Acids
Volume 7, Issue 3, Pages (September 2016)
Molecular Therapy - Methods & Clinical Development
High Frequency Retrotransposition in Cultured Mammalian Cells
Volume 18, Issue 2, Pages (April 2005)
Molecular Therapy - Nucleic Acids
Simultaneous Reprogramming and Gene Correction of Patient Fibroblasts
Volume 1, Issue 3, Pages (September 2013)
Volume 14, Issue 6, Pages (February 2016)
BRCA2 Is Required for Homology-Directed Repair of Chromosomal Breaks
TRF2 Protects Human Telomeres from End-to-End Fusions
NILV‐S/MAR‐mediated transgene expression
Generation of a stable packaging cell line producing high-titer PPT-deleted integration- deficient lentiviral vectors  Peirong Hu, Yedda Li, Mark S Sands,
Targeted Myostatin Gene Editing in Multiple Mammalian Species Directed by a Single Pair of TALE Nucleases  Li Xu, Piming Zhao, Andrew Mariano, Renzhi.
Volume 2, Issue 1, Pages (January 2014)
Volume 20, Issue 8, Pages (August 2017)
Olivier Humbert, Nancy Maizels  Molecular Therapy - Nucleic Acids 
Toyoaki Natsume, Tomomi Kiyomitsu, Yumiko Saga, Masato T. Kanemaki 
Volume 15, Issue 2, Pages (February 2007)
Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR/Cas9-Mediated Gene Editing  Pavel I. Ortinski, Bernadette.
Volume 15, Issue 11, Pages (November 2007)
Volume 15, Issue 4, Pages (April 2007)
Volume 21, Issue 8, Pages (August 2013)
Morvarid Moayeri, Teresa S. Hawley, Robert G. Hawley  Molecular Therapy 
Assessing the Functional Characteristics of Synonymous and Nonsynonymous Mutation Candidates by Use of Large DNA Constructs  A.M. Eeds, D. Mortlock, R.
Volume 22, Issue 4, Pages (April 2014)
Tagging of the endogenous Py03652 gene with the gfp gene in Plasmodium yoelii. Tagging of the endogenous Py03652 gene with the gfp gene in Plasmodium yoelii.
Molecular Therapy - Nucleic Acids
NILV‐S/MAR‐mediated transgene expression
BAC recombineering, gene targeting and RMCE strategies.
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Jiamiao Lu, Feijie Zhang, Mark A Kay  Molecular Therapy 
Molecular Therapy - Methods & Clinical Development
Volume 9, Issue 5, Pages (May 2004)
Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner  Juan Lama, Aram Mangasarian,
High-level production of replication-defective human immunodeficiency type 1 virus vector particles using helper-dependent adenovirus vectors  Yani Hu,
Volume 7, Issue 3, Pages (March 2003)
Volume 11, Issue 5, Pages (May 2005)
Volume 27, Issue 13, Pages e4 (June 2019)
Molecular Therapy - Methods & Clinical Development
Presentation transcript:

NGEC Applications Meeting Mike Certo Scharenberg Lab

Transient DR-GFP Assay

WT-7C+11C -7C +11C Ani WT-7C+11C -7C +11C Ani WT-7C+11C -7C +11C Ani WT-7C+11C -7C +11C Ani Substrate: In-Vitro recSce Cleavage of Canine Site linearized 5units0.5units 0.2units An endogenous intergenic 2-off Sce site (-7C +11C) in the Canine genome is a potential safe harbor site for transgenes. Linearized plasmid DNA containing the indicated targets was digested with recombinant I-SceI to assess cleavability.

Transient DR-GFP Assay for In-vivo Enzyme/Target Discrimination GFP control Sce DR alone Sce DR + I-SceI Untreated

I-AniI vs Y2 In-Vivo untreatedAni-DRAni-DR + AniAni-DR + Ani-Y2

I-SceI is Intolerant of C-terminal Fluorescent Protein Fusions - I-SceI -mCherry I-SceI-3xG4S -mCherry I-SceI-IRES -mCherry Sce DR-GFP Transient DR assay to assess functionality of Sce-Cterm fusions

Conclusions: Transient DR-GFP Assay Can be used to quickly discern activity between enzyme variants and targets. Signal can be adjusted by varying DNA input. Provides information in the context of mammalian gene conversion. Experimental -7C + 11C Canine target will likely require enzyme optimization WT I-AniI induces gene conversion at suboptimal rates Y2 variant performs similar to I-SceI I-SceI is non-permissive of C terminal fluorescent fusions, but IRES allows for enzyme function and detection

Blue-Green Color Change

2 nucleotide changes switch fluorophores Trans-HDR Blue-Green Reporter Swappable HE cleavage site Intron allows use of >1Kb repair template T Y Fluorophore “Switch” Repair Template Asc1Age1 eGFP T Y eGFP Repair Product S H Asc1Age1 eBFP 1-52 eBFP Intron 70 bp eBFP HE Substrate Swappable HE substrate

Lenti Viral Vector for Color Change Reporter pRRL SFFV eBFP IRES Puro Sce WPRE 9215 bp AmpR Gag (SL4) PuroR eBFP N-term eBFP mouse IL2Rgamma Intron 4 RU5 U3*RU5 SFFV PBS (SL123) RRE cPPT WPRE PolyA IRES SD YTRAY Branch point SA I-Sce target site RSV F1 ORI SV40 pA/ORI Nef* S65 H66

Color Change Reporter Transduction 100, T cells transduced with either RRL eGFPsce reporter or RRL eBFPsce reporter. Based on eGFP positive cells at 1uL of viral supernatant, titer is estimated at ~ 2 x10 I.U./ml giving M.O.I ~ 0.5. This should yeild a population averaging 1 integration per cell. 7

Single Cell Sorting We gated on increasingly stringent populations (3% to 0.5%) and single cell sorted into 96 wells plates. As clones come up, we will re-analyze by flow for expression, and conduct southern blots to determine single cell integrants.

Integrated Reporter Is Unspliced across intron within intron Across Intron Non-spliced product yeilds: 1300bp Spliced product yeilds: 720bp Within Intron Non-spliced product yeilds: 1140bp Spliced product yeilds: no band 1500bp 1000bp No unspliced products were detected PCR of Genomic DNA Following Transduction untreated Sce I-SceI Digestion of gDNA PCR Product 1500bp 1000bp I-SceI site is cleavable The PCR product of the integrated reporter was digested with recombinant Sce to ensure the presence of a functional target

untreated repair template alonesce expression aloneSce + repair template Gene Conversion Polyclonal population of puro selected cells were transfected with a plasmid containing I-Sce expression and an eGFP repair template. Cells were FACS 5 days post transfection.

Effect of Homology and Track Length on Conversion in Trans untreatedrepairSce Sce + repair 1uG Sce + repair 2uG Sce + repair 5uG untreatedrepairSce Sce + repair 1uG Sce + repair 2uG Sce + repair 5uG eBFP azBFP

Disparity of Gene Conversion at Distinct Loci Single cell clones from the polyclonal population were subjected to gene conversion assay 293Tpolyclonal Single Cell Clones

IDLV Gene Conversion ~ 60,000nG p24 untreated repair alone Sce aloneSce + repair

Assay eBFP likely detectable as single integrant at particular loci Conversion rates of ~ 3% Blue to Green? Fluorescent protein stability an issue? Conclusions: Blue-Green Color Change Experiments Single cell clones exhibit differential conversion ability Low expression off IDLV contributes to inefficient repair